Clinical pharmacokinetics of salmeterol

Clinical Pharmacokinetics

Volumn 41, Issue 1, 2002, Pages 19-30

  Cazzola, Mario ^a,c   Testi, Renato ^a   Matera, Maria Gabriella ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALMETEROL; SALMETEROL XINAFOATE;

ANALYTIC METHOD; BINDING AFFINITY; BRONCHODILATATION; DESENSITIZATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; HUMAN; ISOMERISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION;

EID: 0036168340     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241010-00003     Document Type: Review

References (52)

1. Pharmacokinetic optimisation of asthma treatment
2. Pharmacodynamics and clinical management
3. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics
4. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration
5. Clinical pharmacokinetics of β-agonists
6. Long-term drug treatment of asthma in children
7. Therapeutic aerosols
8. Dose-response of inhaled drugs in asthma. An update
9. Metered dose inhaler salbutamol treatment of asthma in the ED: Comparison of two doses with plasma levels
10. The pharmacology of salmeterol
11. Salmeterol, a novel, long-acting β2-adrenoceptor agonist: Characterization of pharmacological activity in vitro and in vivo
12. Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting 132-adrenoceptor agonists
13. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers
14. Why are long-acting beta-adrenoceptor agonists long-acting?
15. Identification of a key amino acid of the β2-adrenergic receptor for high affinity binding of salmeterol
16. Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the β2-adrenergic receptor
17. Kinetic analysis of drug-receptor interactions of long-acting β2 sympathomimetics in isolated receptor membranes: Evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase
18. 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro
19. A way of looking at agonism and antagonism: Lessons from salbutamol, salmeterol and other β-adrenoceptor agonists
20. The β-adrenoceptor
21. Effect of inhaled formoterol and budesonide on exacerbations of asthma
22. Inhaled salmeterol in asthmatic patients: An evaluation of asthma symptoms and the possible development of tachyphlyaxis
23. Regulation of the β2-adrenergic receptor by the long-acting agonist salmeterol in human bronchial epithelial cells
24. Relaxation kinetics of formoterol and salmeterol in the guinea pig trachea in vitro
25. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: Differences in maximum relaxant effect and potency but not in functional antagonism
26. Exosites: Their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonises
27. Pharmacodynamic and pharmacokinetic aspects on the transport of bronchodilator drugs through the tracheal epithelium of the guinea-pig
28. Time course and relative dose potency of systemic effects from salbutamol and salmeterol in healthy subjects
29. Dose-response study with high-dose inhaled salmeterol in healthy subjects
30. Safety and appropriate use of salmeterol in the treatment of asthma
31. Cardiotoxic effects of salmeterol in comparison with salbutamol on the isolated perfused Langendorff-heart of the rat
32. The contribution of the swallowed fractions of an inhaled dose of salmeterol to its systemic effects
33. Systemic dynamic responses to oral doses of salmeterol in healthy subjects - Effect of activated charcoal
34. Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma
35. GC-MS determination of salmeterol in human plasma following inhaled administration
36. Determination of salmeterol in rat and dog plasma by high-performance liquid chromatography with fluorescence detection
37. The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate
38. The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and LC-MS-MS
39. Coupled column chromatography in chiral separation of salmeterol
40. Rapid chiral high-performance liquid chromatographic assay for salmeterol and α-hydroxysalmeterol. Application to in vitro metabolism studies
41. Disposition of salmeterol xinafoate in laboratory animals and humans
42. The characterisation of the major metabolites of salmeterol in the dog
43. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
44. Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma
45. The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A
46. Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions
47. Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy
48. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults
49. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and non-smokers
50. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?